These findings indicate that the downregulation of IDO controls peritoneal dissemination of ovarian cancer by promoting NK cell accumulation in tumors, suggesting that IDO is a useful therapeutic target for patients with ovarian cancer. This evidence concerns the gene IDO1 and ovarian carcinoma.